Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Baseline disease modifying therapies (DMTs)----1件: 13 💬
2BG00012 (DMF)----1件: 13 💬
3BG00012 (DMF) (Tecfidera®.)----1件: 13 💬
4Biologic DMARD----2件: 46, 271 💬
5Biologic DMARDs----1件: 107 💬
6Biological DMARDs----2件: 86, 107 💬
7Classic DMARDs treatment group----1件: 46 💬
8Co-medication: Synthetic DMARDs----1件: 46 💬
9Combination of DMARDs----1件: 107 💬
10Conventional DMARD combination----1件: 46 💬
11Conventional DMARDs----1件: 46 💬
12Conventional Synthetic DMARD----1件: 46 💬
13CP-690-550-10 (DMID D1600180)----1件: 107 💬
14Daunorubicin
(DM)
1件: Daunorubicin1件: Daunorubicin (DM) 💬2件: TOP2A,
TOP2B 💬
1件: Platinum drug resistance 💬1件: 65 💬
15Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)2件: Dextromethorphan (Bronchophan Forte DM Syr),
Quinidine
2件: Dextromethorphan ,
Quinidine 💬
11件: GRIN1,
GRIN2A,
GRIN2B,
GRIN2C,
GRIN2D,
SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A,
SIGMAR1 💬
22件: Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway 💬1件: 8 💬
16Dimethyl Fumarate (DMF)1件: Dimethyl fumarate1件: Dimethyl fumarate 💬1件: KEAP1 💬6件: Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬3件: 13, 51, 86 💬
17Dimethyl fumarate [DMF]1件: Dimethyl fumarate1件: Dimethyl fumarate 💬1件: KEAP1 💬6件: Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬1件: 13 💬
18Dimethyl sulfoxide (DMSO)1件: Dimethyl sulfoxide (DMSO)1件: Dimethyl sulfoxide 💬--1件: 226 💬
19Disease modifying treatment (DMT)----1件: 13 💬
20Disease-modifying antirheumatic drugs (DMARDs)----1件: 46 💬
21DM----2件: 6, 8 💬
22DM-1992----1件: 6 💬
23DMARD----1件: 46 💬
24DMARD cessation----1件: 46 💬
25DMARD maintenance----1件: 46 💬
26DMARD Therapy----1件: 46 💬
27DMARDS----2件: 46, 271 💬
28DMARDs (disease-modifying antirheumatic drugs)----1件: 46 💬
29DMARDs (methotrexate1件: Methotrexate1件: Methotrexate 💬2件: DHFR,
DHFR2 💬
5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 46 💬
30DMARDs or Biologics----1件: 46 💬
31DMPS1件: 2,3-Dimercapto-1-propanesulfonic acid (DMPS)---1件: 171 💬
32DMSA1件: Succimer (DMSA)1件: Succimer 💬--1件: 171 💬
33DMSO1件: Dimethyl sulfoxide (DMSO)1件: Dimethyl sulfoxide 💬--1件: 226 💬
34DMSO cocktail1件: Dimethyl sulfoxide (DMSO)1件: Dimethyl sulfoxide 💬--1件: 226 💬
35DMT----1件: 13 💬
36DMT continuation----1件: 13 💬
37DMX-200----1件: 222 💬
38Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc1件: Etanercept1件: Etanercept 💬2件: LTA,
TNF 💬
67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46 💬
39Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS----1件: 13 💬
40First line DMT----1件: 13 💬
41HUC-MSC + DMARDs----1件: 46 💬
42Injectable MS DMT----1件: 13 💬
43IONIS-DMPKRx----1件: 113 💬
44Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)----1件: 46 💬
45Non-Biologic DMARDs----3件: 46, 86, 107 💬
46Non-biological DMARDs----1件: 46 💬
47Nonbiologic DMARDs of investigator's choice----1件: 46 💬
48Patient treated with DMARD----1件: 46 💬
49Permitted DMARDs----1件: 46 💬
50Phase 1: Conventiaonal DMARD----1件: 46 💬
51Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)----1件: 46 💬
52Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)----1件: 46 💬
53Standard MS DMT----1件: 13 💬
54Standard MS DMTs----1件: 13 💬
55Synthetic DMARD(s)----1件: 46 💬
56Targeted synthetic DMARD class----1件: 46 💬
57Therapy with disease-modifying anti rheumatic drugs (DMARD)----1件: 46 💬
58TNF-a antagonists, non-TNFs, DMARD non-biologics----2件: 46, 271 💬
59Trivalent chromium versus synthetic and/ or biological DMARDs1件: Chromium---1件: 46 💬
60UC-MSC+DMARDS----1件: 46 💬
61Vinblastine, vincristine, prednisone, daunorubicin
(DM)
4件: Daunorubicin,
Prednisone,
Vinblastine,
Vincristine
4件: Prednisone ,
Daunorubicin (DM),
Vinblastine ,
Vincristine 💬
12件: NR3C1,
TOP2A,
TOP2B,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬
12件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Platinum drug resistance, Prion disease, Salmonella infection 💬1件: 65 💬